Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Harvard Bioscience (HBIO) over the last 12 years, with Q3 2025 value amounting to $660755.0.

  • Harvard Bioscience's Gains from Investment Securities fell 2548.28% to $660755.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $660755.0, marking a year-over-year decrease of 2548.28%. This contributed to the annual value of $827458.0 for FY2024, which is 1045.48% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Gains from Investment Securities is $660755.0, which was down 2548.28% from $708793.0 recorded in Q2 2025.
  • Harvard Bioscience's Gains from Investment Securities' 5-year high stood at $2.1 million during Q4 2023, with a 5-year trough of $47000.0 in Q1 2024.
  • For the 5-year period, Harvard Bioscience's Gains from Investment Securities averaged around $964498.6, with its median value being $896953.0 (2024).
  • As far as peak fluctuations go, Harvard Bioscience's Gains from Investment Securities soared by 13352.44% in 2023, and later plummeted by 9598.28% in 2024.
  • Over the past 5 years, Harvard Bioscience's Gains from Investment Securities (Quarter) stood at $861000.0 in 2021, then soared by 49.58% to $1.3 million in 2022, then surged by 60.88% to $2.1 million in 2023, then plummeted by 38.32% to $1.3 million in 2024, then tumbled by 48.3% to $660755.0 in 2025.
  • Its Gains from Investment Securities stands at $660755.0 for Q3 2025, versus $708793.0 for Q2 2025 and $75000.0 for Q1 2025.